ClinicalTrials.gg
CompletedNCT02721017Updated May 5, 2021Results posted

Cryoanalgesia vs. Epidural in the Nuss Procedure

A Phase 4 interventional study of Cryoanalgesia and Thoracic epidural (ropivicaine, fentanyl) in Pectus Excavatum and Funnel Chest, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2021-05-05.

Sponsored by University of California, San Francisco · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether cryoanalgesia provides better pain control for minimally invasive pectus excavatum repair (the Nuss procedure) than thoracic epidural.

Read the detailed description

Pain control is a major challenge for physicians, who must ensure appropriate and effective pain control for their patients, while remaining mindful of the many negative effects of opioid dependence and addiction. Nowhere is there a more pressing need than in children and young adults, who are at high risk for drug abuse, and in post-operative care, since post-operative opioid use can be a starting point for long-term pain issues. Postoperative pain control in the Nuss procedure, minimally invasive repair of the congenital chest wall deformity known as pectus excavatum, remains a significant problem for the 3000 patients who undergo this procedure each year, mostly adolescents and young adults. Many multimodal analgesic regimens have been tried, but optimal treatment remains unknown.

This study will test a novel and promising strategy of using intra-operative cryoanalgesia during the Nuss procedure. Cryoanalgesia is the localized, temporary freezing of peripheral nerves, which is performed at the time of the Nuss procedure. The study is a 20-subject prospective, randomized pilot trial comparing cryoanalgesia to thoracic epidural analgesia for post-operative pain control in patients undergoing the Nuss procedure. Subjects will be recruited from patients already scheduled for a Nuss procedure at our institution, and will undergo 1:1 randomization to either cryoanalgesia or thoracic epidural analgesia for perioperative pain control. During their hospitalization, patients' opiate usage will be prospectively recorded, and pain will be assessed twice per day. Upon discharge, patients will maintain a log of their opiate use, and will return to clinic at 2 weeks, 1 month, 3 months, and 1 year after Nuss procedure for post-operative assessment. Primary outcome is length of perioperative hospitalization, an objective measure that synthesizes many different aspects of a procedure and its subsequent post-operative course, including pain control. Secondary outcomes are post-operative narcotic usage and direct cost of perioperative hospitalization. Side effects of both interventions will also be assessed.

This will be the first systematic investigation of cryoanalgesia for local nerve block in a thoracoscopic procedure, and the first study involving its use in adolescents and young adults. The results will have direct application for those undergoing the Nuss procedure to repair pectus excavatum. Investigators will also delineate a reproducible protocol for delivering cryoanalgesia thoracoscopically, to ensure others can safely and effectively use this method if it proves beneficial. Although the focus is on the small subset of patients who undergo the Nuss procedure, if a standardized approach to cryoanalgesia delivery in a thoracoscopic procedure has a positive effect on patient outcomes and cost of hospitalization, the technique could be applied to a variety of surgical procedures, as well as for other neuropathic pain.

02

Conditions studied

  • Pectus Excavatum
  • Funnel Chest

Browse trials for

Keywords

  • Nuss
  • Nuss Procedure
  • pectus excavatum
  • cryoanalgesia
03

In context

Funnel Chest

79 studies on the registry are indexed under Funnel Chest; 10 are open to participants now.

This study's enrollment of 20 is below the median of 40 across 46 interventional studies indexed under Funnel Chest.

Browse Funnel Chest studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • scheduled for Nuss procedure for pectus excavatum correction
  • at least 13 years old at the time of the procedure

Exclusion criteria

Exclusion Criteria:

  • age less than 13 years at time of procedure
  • use of pain medication prior to procedure
  • pectus carinatum, Poland's syndrome, or any chest wall anomaly other than pectus excavatum
  • previous repair of pectus excavatum by any technique
  • previous thoracic surgery
  • congenital heart disease
  • bleeding dyscrasia
  • major anesthetic risk factors or history of previous problem with anesthesia
  • pregnancy
  • inability to communicate in English
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Cryoanalgesia

    Cryoanalgesia performed thoracoscopically under general anesthesia by the patient's surgeon at the time of the Nuss procedure

    Device: Cryoanalgesia

  • Active comparator
    Thoracic Epidural

    Thoracic epidural (ropivicaine, fentanyl).

    Drug: Thoracic epidural (ropivicaine, fentanyl)

Interventions

  • DeviceCryoanalgesia

    Also known as: AtriCure, cryoprobe, nerve freezing

  • DrugThoracic epidural (ropivicaine, fentanyl)

    Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.

    Also known as: Epidural

06

What researchers measure

Primary outcomes

  1. Length of Hospitalization

    the length of the patient's in-hospital stay following admission for Nuss procedure

    Time frame: estimated one week or less

Secondary outcomes

  1. Narcotic Usage

    Inpatient narcotic usage

    Time frame: Post Operative Hospital Stay

  2. Mean Neuropathic Pain Score at One Year

    Neuropathic specific pain (described as "burning", "electrical" or "tingling" sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).

    Time frame: one year

  3. Cost Analysis

    cost analysis of initial hospitalization following Nuss procedure

    Time frame: estimated one week

07

Results

Posted May 5, 2021

Participant flow

Twenty consecutive patients were recruited from those scheduled for the Nuss procedure.

Hospital Stay
Participant flow — Hospital Stay
MilestoneCryoanalgesiaThoracic Epidural
Started1010
Completed1010
Not completed00
Participant Follow Up
Participant flow — Participant Follow Up
MilestoneCryoanalgesiaThoracic Epidural
Started1010
Completed1010
Not completed00

Outcome measures

PrimaryLength of Hospitalization

the length of the patient's in-hospital stay following admission for Nuss procedure

Time frame:
estimated one week or less
Reported as:
Median · Length of Stay (Post-Operative Days)
Length of Hospitalization
Length of Stay (Post-Operative Days)CryoanalgesiaThoracic Epidural
Length of Hospitalization3 (2 to 4)5 (4 to 6)
SecondaryNarcotic Usage

Inpatient narcotic usage

Time frame:
Post Operative Hospital Stay
Reported as:
Mean · mg
Narcotic Usage
mgCryoanalgesiaThoracic Epidural
Narcotic Usage268 ± 165.2684 ± 191.8
SecondaryMean Neuropathic Pain Score at One Year

Neuropathic specific pain (described as "burning", "electrical" or "tingling" sensations) was assessed by study questionnaire via numerical pain scale (1 to 10, with 10 representing a maximum score, or worst pain possible).

Time frame:
one year
Reported as:
Mean · score on a scale
Mean Neuropathic Pain Score at One Year
score on a scaleCryoanalgesiaThoracic Epidural
Mean Neuropathic Pain Score at One Year2.4 ± 2.691.9 ± 1.34
SecondaryCost Analysis

cost analysis of initial hospitalization following Nuss procedure

Time frame:
estimated one week

No measurements were reported for this outcome.

Adverse events

Collected over All adverse events reported post operatively at the 2 week, 1 month, 3 month and 1 year follow up points were collected. In addition all serious adverse events that occurred following enrollment were as well collected. The collection period for all serious adverse events began after informed consent was obtained and ended after procedures for the final study visit had been completed at the 1 year post-operative mark.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cryoanalgesia0/10 (0%)0/10 (0%)0/10 (0%)
Thoracic Epidural0/10 (0%)2/10 (20%)0/10 (0%)
Most frequent serious events
Most frequent serious events
EventCryoanalgesiaThoracic Epidural
Symptomatic PneumothoraxRespiratory, thoracic and mediastinal disorders0/101/10
Urinary RetentionRenal and urinary disorders0/101/10
ParaplegiaNervous system disorders0/100/10
Wound InfectionInfections and infestations0/100/10
Infection from indwelling thoracic epidural catheterInfections and infestations0/100/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CryoanalgesiaThoracic EpiduralTotal
<=18 years4711
Between 18 and 65 years639
>=65 years000
Age, Continuous
Age, Continuous(years)CryoanalgesiaThoracic EpiduralTotal
Mean20.9 (14 to 31)16.1 (13 to 21)18.5 (13 to 31)
Sex: Female, Male
Sex: Female, Male(Participants)CryoanalgesiaThoracic EpiduralTotal
Female123
Male9817
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)CryoanalgesiaThoracic EpiduralTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)CryoanalgesiaThoracic EpiduralTotal
United States101020
08

Study locations

1 site
  • UCSF-Benioff Children's Hospital
    San Francisco, California 94158, United States
09

References and documents

Publications

  • Graves C, Idowu O, Lee S, Padilla B, Kim S. Intraoperative cryoanalgesia for managing pain after the Nuss procedure. J Pediatr Surg. 2017 Jun;52(6):920-924. doi: 10.1016/j.jpedsurg.2017.03.006. Epub 2017 Mar 16. PubMed 28341230 ↗
  • Graves CE, Moyer J, Zobel MJ, Mora R, Smith D, O'Day M, Padilla BE. Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial. J Pediatr Surg. 2019 Nov;54(11):2250-2256. doi: 10.1016/j.jpedsurg.2019.02.057. Epub 2019 Mar 17. PubMed 30935731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Aug 2018, 27 months.

Results were first posted in May 2021, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Mar 28, 2016
StartActual
May 2016
Primary completionActual
Aug 28, 2018
CompletionActual
Sep 2018
Results first posted
May 5, 2021
Last update
May 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02721017
Responsible party
Sponsor
First posted
Mar 28, 2016
Start date
May 2016
Primary completion
Aug 28, 2018
Completion
Sep 2018
Results posted
May 5, 2021
Last update
May 5, 2021

Study contacts

Benjamin Padilla, MD
principal investigator · 415-370-2835

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion